Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report)’s share price traded up 2.7% during mid-day trading on Monday . The company traded as high as $3.30 and last traded at $2.69. 578,951 shares were traded during trading, an increase of 519% from the average session volume of 93,476 shares. The stock had previously closed at $2.62.
Salarius Pharmaceuticals Stock Performance
The company’s 50-day moving average price is $1.64 and its 200 day moving average price is $1.78. The stock has a market cap of $3.87 million, a PE ratio of -0.33 and a beta of 0.83.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Further Reading
- Five stocks we like better than Salarius Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- What is the Dogs of the Dow Strategy? Overview and Examples
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
